|
EP1401850A1
(en)
|
2001-06-20 |
2004-03-31 |
Nuevolution A/S |
Nucleoside derivatives for library preparation
|
|
US7413854B2
(en)
|
2002-03-15 |
2008-08-19 |
Nuevolution A/S |
Method for synthesising templated molecules
|
|
US10730906B2
(en)
|
2002-08-01 |
2020-08-04 |
Nuevolutions A/S |
Multi-step synthesis of templated molecules
|
|
EP1558744B1
(en)
|
2002-10-30 |
2011-06-15 |
Nuevolution A/S |
Enzymatic encoding
|
|
WO2004056994A2
(en)
|
2002-12-19 |
2004-07-08 |
Nuevolution A/S |
Quasirandom structure and function guided synthesis methods
|
|
US20070026397A1
(en)
|
2003-02-21 |
2007-02-01 |
Nuevolution A/S |
Method for producing second-generation library
|
|
EP1670939B1
(en)
|
2003-09-18 |
2009-11-04 |
Nuevolution A/S |
A method for obtaining structural information concerning an encoded molecule and method for selecting compounds
|
|
RS52545B
(sr)
|
2004-04-07 |
2013-04-30 |
Novartis Ag |
Inhibitori protein apoptoze (iap)
|
|
AU2005274937B2
(en)
|
2004-07-15 |
2011-08-18 |
Medivir Ab |
IAP binding compounds
|
|
KR20120127754A
(ko)
|
2004-12-20 |
2012-11-23 |
제넨테크, 인크. |
Ｉａｐ의 피롤리딘 억제제
|
|
PL1851200T3
(pl)
|
2005-02-25 |
2014-06-30 |
Tetralogic Pharm Corp |
Dimeryczne inhibitory IAP
|
|
US7772177B2
(en)
|
2005-05-18 |
2010-08-10 |
Aegera Therapeutics, Inc. |
BIR domain binding compounds
|
|
WO2007003961A2
(en)
*
|
2005-06-30 |
2007-01-11 |
Prosidion Limited |
Gpcr agonists
|
|
US20100256046A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
DE102005046907A1
(de)
|
2005-09-30 |
2007-04-12 |
Voith Patent Gmbh |
Verfahren und Vorrichtung zur Herstellung einer Tissuebahn
|
|
WO2007048224A1
(en)
|
2005-10-25 |
2007-05-03 |
Aegera Therapeutics Inc. |
Iap bir domain binding compounds
|
|
EP2341140B1
(en)
|
2005-12-01 |
2017-07-19 |
Nuevolution A/S |
Enzymatic encoding methods for efficient synthesis of large libraries
|
|
AU2006340014B2
(en)
|
2005-12-19 |
2012-12-20 |
Genentech, Inc. |
Inhibitors of IAP
|
|
TWI543988B
(zh)
|
2006-03-16 |
2016-08-01 |
科學製藥股份有限公司 |
結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
|
|
AU2007250443B2
(en)
|
2006-05-16 |
2013-06-13 |
Pharmascience Inc. |
IAP BIR domain binding compounds
|
|
US20100056495A1
(en)
*
|
2006-07-24 |
2010-03-04 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014263A2
(en)
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap antagonists
|
|
US20100113326A1
(en)
*
|
2006-07-24 |
2010-05-06 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
EP2049524A2
(en)
|
2006-07-24 |
2009-04-22 |
Tetralogic Pharmaceuticals Corporation |
Iap inhibitors
|
|
WO2008014229A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
PE20110217A1
(es)
|
2006-08-02 |
2011-04-01 |
Novartis Ag |
DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
|
|
CA2666112A1
(en)
*
|
2006-10-12 |
2008-04-17 |
Novartis Ag |
Pyrrolydine derivatives as iap inhibitors
|
|
EP2125809A1
(en)
*
|
2006-12-19 |
2009-12-02 |
Genentech, Inc. |
Imidazopyridine inhibitors of iap
|
|
JP5454943B2
(ja)
|
2007-04-12 |
2014-03-26 |
ジョイアント ファーマスーティカルズ、インク． |
抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
|
|
CL2008001234A1
(es)
|
2007-04-30 |
2008-09-22 |
Genentech Inc |
Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
|
|
EP2156189A1
(en)
*
|
2007-05-07 |
2010-02-24 |
Tetralogic Pharmaceuticals Corp. |
Tnf gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins
|
|
JP5176452B2
(ja)
*
|
2007-09-27 |
2013-04-03 |
住友化学株式会社 |
光学活性なテトラヒドロピラニルグリシン化合物の製造方法
|
|
KR20100110870A
(ko)
*
|
2008-01-11 |
2010-10-13 |
제넨테크, 인크. |
Ｉａｐ의 억제제
|
|
WO2009094224A1
(en)
|
2008-01-25 |
2009-07-30 |
Millennium Pharmaceuticals, Inc. |
Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
|
|
TW201011006A
(en)
*
|
2008-06-16 |
2010-03-16 |
Nuevolution As |
IAP binding compounds
|
|
AU2009279924B2
(en)
|
2008-08-02 |
2014-10-02 |
Genentech, Inc. |
Inhibitors of IAP
|
|
NZ590500A
(en)
*
|
2008-08-16 |
2012-06-29 |
Genentech Inc |
Azaindole inhibitors of iap
|
|
US9139589B2
(en)
|
2009-01-30 |
2015-09-22 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
US9090601B2
(en)
|
2009-01-30 |
2015-07-28 |
Millennium Pharmaceuticals, Inc. |
Thiazole derivatives
|
|
RU2404166C1
(ru)
*
|
2009-04-14 |
2010-11-20 |
Учреждение Российской Академии Наук Институт Нефтехимии И Катализа Ран |
Способ получения 1-ацетилизохинолина
|
|
US8283372B2
(en)
*
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
|
WO2011016576A1
(en)
|
2009-08-04 |
2011-02-10 |
Takeda Pharmaceutical Company Limited |
Alanine derivatives as inhibitors of apoptosis proteins
|
|
AU2010283748A1
(en)
|
2009-08-12 |
2012-02-09 |
Novartis Ag |
Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein
|
|
CN102612651A
(zh)
|
2009-09-18 |
2012-07-25 |
诺瓦提斯公司 |
Iap抑制剂化合物的生物标志物
|
|
EP2493879B1
(en)
|
2009-10-28 |
2014-05-14 |
Joyant Pharmaceuticals, Inc. |
Dimeric smac mimetics
|
|
US8362068B2
(en)
*
|
2009-12-18 |
2013-01-29 |
Idenix Pharmaceuticals, Inc. |
5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
|
|
NZ602368A
(en)
|
2010-02-12 |
2014-10-31 |
Pharmascience Inc |
Iap bir domain binding compounds
|
|
US11225655B2
(en)
|
2010-04-16 |
2022-01-18 |
Nuevolution A/S |
Bi-functional complexes and methods for making and using such complexes
|
|
WO2012021611A1
(en)
|
2010-08-11 |
2012-02-16 |
Millennium Pharmaceuticals, Inc. |
Heteroaryls and uses thereof
|
|
CN103443068A
(zh)
|
2011-03-22 |
2013-12-11 |
先正达参股股份有限公司 |
杀虫化合物
|
|
GB201106817D0
(en)
|
2011-04-21 |
2011-06-01 |
Astex Therapeutics Ltd |
New compound
|
|
CN102757426A
(zh)
*
|
2011-04-28 |
2012-10-31 |
中国医学科学院医药生物技术研究所 |
一种苯并异恶唑基取代的噻唑类化合物、制备方法及用途
|
|
NO2755614T3
(enExample)
*
|
2012-01-03 |
2018-03-31 |
|
|
|
HK1208875A1
(en)
|
2012-01-12 |
2016-03-18 |
耶鲁大学 |
Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
|
|
WO2013166344A1
(en)
|
2012-05-04 |
2013-11-07 |
Novartis Ag |
Biomarkers for iap inhibitor therapy
|
|
GB201218850D0
(en)
|
2012-10-19 |
2012-12-05 |
Astex Therapeutics Ltd |
Bicyclic heterocycle compounds and their uses in therapy
|
|
GB201218864D0
(en)
|
2012-10-19 |
2012-12-05 |
Astex Therapeutics Ltd |
Bicyclic heterocycle compounds and their uses in therapy
|
|
US9980973B2
(en)
|
2012-10-19 |
2018-05-29 |
Astex Therapeutics Limited |
Bicyclic heterocycle compounds and their uses in therapy
|
|
GB201218862D0
(en)
|
2012-10-19 |
2012-12-05 |
Astex Therapeutics Ltd |
Bicyclic heterocycle compounds and their uses in therapy
|
|
JP6587142B2
(ja)
|
2013-02-15 |
2019-10-09 |
国立大学法人 東京医科歯科大学 |
マイクロｒｎａからなるがん治療剤
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
EA035253B1
(ru)
|
2013-03-15 |
2020-05-21 |
Новартис Аг |
Лекарственные конъюгаты антител
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
CN105829310B
(zh)
|
2013-12-20 |
2019-04-12 |
阿斯特克斯治疗有限公司 |
双环杂环化合物及其治疗用途
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US10300074B2
(en)
|
2014-06-04 |
2019-05-28 |
Sanford Burnham Prebys Medical Discovery Institute |
Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
MA40513A
(fr)
|
2014-08-12 |
2017-06-21 |
Novartis Ag |
Conjugués médicament-anticorps anti-cdh6
|
|
CA2974367A1
(en)
|
2015-01-20 |
2016-07-28 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of the androgen receptor
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
US20180147202A1
(en)
|
2015-06-05 |
2018-05-31 |
Arvinas, Inc. |
TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
EP3535265A4
(en)
|
2016-11-01 |
2020-07-08 |
Arvinas, Inc. |
PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
|
|
RS64976B1
(sr)
|
2016-12-01 |
2024-01-31 |
Arvinas Operations Inc |
Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora
|
|
RU2019121527A
(ru)
|
2016-12-23 |
2021-01-15 |
Эрвинэс Оперейшнс, Инк. |
Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения
|
|
WO2018118598A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
JP7679173B2
(ja)
|
2016-12-23 |
2025-05-19 |
アルビナス・オペレーションズ・インコーポレイテッド |
Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
CN117551089A
(zh)
|
2017-01-26 |
2024-02-13 |
阿尔维纳斯运营股份有限公司 |
雌激素受体蛋白水解调节剂及相关使用方法
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
EP3592868B1
(en)
|
2017-03-06 |
2022-11-23 |
Novartis AG |
Methods of treatment of cancer with reduced ubb expression
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
MX2019014023A
(es)
|
2017-05-24 |
2020-02-17 |
Novartis Ag |
Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
|
|
CN111107868A
(zh)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
US20210371459A1
(en)
*
|
2017-07-25 |
2021-12-02 |
Hepagene Therapeutics (HK) Limited |
Dimeric peptide inhibitors of apoptosis proteins
|
|
BR112020009369A2
(pt)
|
2017-11-13 |
2020-10-13 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd |
miméticos de smac usados como inibidores de iap e seus usos
|
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
TWI812673B
(zh)
|
2018-02-12 |
2023-08-21 |
美商富曼西公司 |
用於防治無脊椎害蟲之萘異噁唑啉化合物
|
|
JP7720698B2
(ja)
|
2018-04-04 |
2025-08-08 |
アルビナス・オペレーションズ・インコーポレイテッド |
タンパク質分解の調節因子および関連する使用方法
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
PL3820573T3
(pl)
|
2018-07-10 |
2024-02-19 |
Novartis Ag |
Pochodne 3-(5-hydroksy-1-oksoizoindolin-2-ylo)piperydyno-2,6-dionu i ich zastosowanie w leczeniu chorób zależnych od palca cynkowego z rodziny ikaros 2 (ikzf2)
|
|
WO2020023851A1
(en)
|
2018-07-26 |
2020-01-30 |
Yale University |
Bifunctional substitued pyrimidines as modulators of fak proteolyse
|
|
JP7297053B2
(ja)
|
2018-08-20 |
2023-06-23 |
アルビナス・オペレーションズ・インコーポレイテッド |
神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
|
|
CN113164775B
(zh)
|
2018-09-07 |
2025-03-18 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法
|
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
CN113271945A
(zh)
|
2018-12-20 |
2021-08-17 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
|
|
JP7607564B2
(ja)
|
2018-12-21 |
2024-12-27 |
ノバルティス アーゲー |
Ｐｍｅｌ１７に対する抗体及びその結合体
|
|
JP7483732B2
(ja)
|
2019-02-15 |
2024-05-15 |
ノバルティス アーゲー |
３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN113543852A
(zh)
|
2019-03-06 |
2021-10-22 |
第一三共株式会社 |
吡咯并吡唑衍生物
|
|
KR20220006611A
(ko)
*
|
2019-05-10 |
2022-01-17 |
치아타이 티안큉 파마수티컬 그룹 주식회사 |
Iap 억제제로서의 smac 모방물의 결정 및 그 제조방법
|
|
CN114867727B
(zh)
|
2019-07-17 |
2025-02-21 |
阿尔维纳斯运营股份有限公司 |
Tau蛋白靶向化合物及相关使用方法
|
|
JP2022542437A
(ja)
|
2019-08-02 |
2022-10-03 |
ランティオペプ ベスローテン ヴェンノーツハップ |
癌の処置に用いるアンジオテンシン２型（ａｔ２）受容体アゴニスト
|
|
KR20220054347A
(ko)
|
2019-08-26 |
2022-05-02 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
|
|
TW202135859A
(zh)
|
2019-12-20 |
2021-10-01 |
瑞士商諾華公司 |
組合療法
|
|
CN113354530B
(zh)
*
|
2020-03-07 |
2025-11-18 |
东莞市东阳光动物保健药品有限公司 |
一种制备4-乙酰基-1-萘甲酸的方法
|
|
HUP2200468A1
(hu)
|
2020-04-29 |
2023-03-28 |
X Chem Zrt |
IAP antagonisták és gyógyászati alkalmazásuk
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US12180193B2
(en)
|
2020-08-28 |
2024-12-31 |
Arvinas Operations, Inc. |
Accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
JP2023541434A
(ja)
|
2020-09-14 |
2023-10-02 |
アルビナス・オペレーションズ・インコーポレイテッド |
エストロゲン受容体の標的化分解のための化合物の結晶性形態
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
KR20230170738A
(ko)
|
2021-04-16 |
2023-12-19 |
노파르티스 아게 |
항체 약물 접합체 및 이의 제조 방법
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
CN119301125A
(zh)
|
2022-07-26 |
2025-01-10 |
诺华股份有限公司 |
Akr1c3依赖性kars抑制剂的晶型
|
|
US11957759B1
(en)
|
2022-09-07 |
2024-04-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
|
|
KR20250151412A
(ko)
|
2023-01-26 |
2025-10-21 |
아비나스 오퍼레이션스, 인코포레이티드 |
세레블론계 kras 분해 단백질 및 이와 관련된 용도
|